EBITDA Margin % is calculated as EBITDA divided by its Revenue. Amarin's EBITDA for the
three
months ended in Mar. 2026 was €-6.9 Mil. Amarin's Revenue for the
three
months ended in Mar. 2026 was €39.0 Mil. Therefore, Amarin's EBITDA margin for the quarter that ended in Mar. 2026 was -17.75%.
Amarin (STU:EH3) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Amarin EBITDA Margin % Related Terms
Amarin EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Amarin's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:EH3 vs SCLX, MIRA, NSRX: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Amarin's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amarin EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amarin's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Amarin's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amarin (STU:EH3) has a EBITDA Margin % of -17.75% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amarin and its competitors. According to the industry distribution chart, Amarin ranks #783 out of 952 companies in the Drug Manufacturers industry, placing it in the top 82.2%.
Is Amarin's EBITDA Margin % too high?
Amarin's current EBITDA Margin % is -17.75%. Based on the distribution chart, Amarin ranks #783 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Amarin has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Amarin's EBITDA Margin % compare to SCLX and MIRA?
According to the Drug Manufacturers industry distribution chart, Amarin ranks #783 out of 952 companies for EBITDA Margin %. This places Amarin in the lower half of its industry. The industry median EBITDA Margin % is 12.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amarin and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amarin's current EBITDA Margin % is -17.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amarin stock overvalued right now?
Amarin (STU:EH3) has a current EBITDA Margin % of -17.75%. The stock's GF Value™ is €10.41, compared to a current price of €13.90 — trading 33.5% above its estimated fair value. The current EBITDA Margin % is -17.75%. Amarin's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Amarin (STU:EH3), the current EBITDA Margin % is -17.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amarin (STU:EH3) Overvalued in 2026?
Based on GuruFocus' analysis, Amarin stock appears to be overvalued.
The current stock price of €13.90 is trading 33.5% above its estimated GF Value™ of €10.41.
Key valuation signals for STU:EH3:
EBITDA Margin %: -17.75%
GF Value™: €10.41 vs. price of €13.90 (33.5% above fair value)
No single metric tells the full story. See the STU:EH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
54GF Score
Get the complete analysis for STU:EH3
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:EH3 has been successfully added to your 
